Ironwood Pharmaceuticals Continues To Expect 2024 Total Revenue Of $350M-$375M Vs. Consensus Of $357.181M

Benzinga
07 Nov 2024
  • Ironwood 2024 Financial Guidance. Ironwood continues to expect:
 

2024 Guidance

(November 7, 2024)

U.S. LINZESS Net Sales$900 - $950 million
Total Revenue$350 - $375 million
Adjusted EBITDA1>$75 million

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10